The Effects of Combination Therapy with Niceritrol and Pravastatin on Hyperlipidaemia  

Oleh:

Kinoshita, K ; Mikuni, Y ; Kudo, M

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Journal of International Medical Research vol. 30 no. 03 (May 2002), page 271-281.
Topik: pravastatin; niceritrol; coenzyme A reductase inhibitor (statin); hyperlipidaemia; combination drug therapy

Ketersediaan

Perpustakaan FK Nomor Panggil: J11.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

In the present study, we evaluated the effects of combination therapy with niceritrol and pravastatin in patients with hyper­lipidaemia. A total of 62 patients with hyperlipidaemia, defined as total cholesterol levels above 220 mg/dl or triglyceride levels above 150 mg/dl, were recruited. Patients were divided into two groups: Group N received initial therapy with niceritrol 750 – 1500 mg/day, and those in Group P, pravastatin 10 mg/day. After 8 weeks, pravastatin 10 mg/day was added to the Group N treatment regimen for a further 8 weeks, while patients in Group P were given niceritrol 750 – 1500 mg/day in addition to pravastatin for 8 weeks. After the 8-week combination therapy study period, total cholesterol levels were 209.6 mg/dl in Group N and 220.7 mg/dl in Group P. Decreased triglyceride and lipoprotein(a) levels and increased high-density lipoprotein cholesterol levels, neither of which were achieved by pravastatin administration alone, were achieved with the combination of pravastatin and niceritrol. We conclude that when a single lipid-lowering drug fails to show therapeutic value, attempting combination therapy with a nicotinic acid preparation and a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is worthwhile.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali